Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 222

1.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
[PubMed - indexed for MEDLINE]
2.

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.

Ricart AD.

Clin Cancer Res. 2011 Oct 15;17(20):6417-27. doi: 10.1158/1078-0432.CCR-11-0486. Review.

PMID:
22003069
[PubMed - indexed for MEDLINE]
Free Article
3.

The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.

Cianfriglia M.

Ann Ist Super Sanita. 2013;49(2):150-68. doi: DOI: 10.4415/ANN_13_02_07. Review.

PMID:
23771260
[PubMed - indexed for MEDLINE]
Free Article
4.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D.

Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Review.

PMID:
23515511
[PubMed - indexed for MEDLINE]
5.

Antibody-drug conjugates: present and future.

Beck A, Reichert JM.

MAbs. 2014 Jan-Feb;6(1):15-7. doi: 10.4161/mabs.27436.

PMID:
24423577
[PubMed - indexed for MEDLINE]
Free Article
6.

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.

Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Review. French.

PMID:
23831822
[PubMed - indexed for MEDLINE]
7.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
[PubMed - indexed for MEDLINE]
8.

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.

Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK.

Pharmacotherapy. 2013 Jan;33(1):93-104. doi: 10.1002/phar.1170. Review.

PMID:
23307550
[PubMed - indexed for MEDLINE]
9.

Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.

Sapra P, Betts A, Boni J.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):541-55. doi: 10.1586/17512433.2013.827405. Epub 2013 Aug 26. Review.

PMID:
23978126
[PubMed - indexed for MEDLINE]
10.

World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.

Beck A, Senter P, Chari R.

MAbs. 2011 Jul-Aug;3(4):331-7. Epub 2011 Jul 1.

PMID:
21691144
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Brentuximab vedotin in anaplastic large cell lymphoma.

Skarbnik AP, Smith MR.

Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27.

PMID:
22449148
[PubMed - indexed for MEDLINE]
12.

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.

Chu YW, Polson A.

Future Oncol. 2013 Mar;9(3):355-68. doi: 10.2217/fon.12.189. Review.

PMID:
23469971
[PubMed - indexed for MEDLINE]
13.

Enthusiasm for antibody-drug conjugates.

Tuma RS.

J Natl Cancer Inst. 2011 Oct 19;103(20):1493-4. doi: 10.1093/jnci/djr422. Epub 2011 Oct 4. No abstract available.

PMID:
21972230
[PubMed - indexed for MEDLINE]
Free Article
14.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR.

J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18.

PMID:
25191794
[PubMed - indexed for MEDLINE]
15.

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM.

Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485. Review.

PMID:
22003072
[PubMed - indexed for MEDLINE]
Free Article
16.

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Senter PD, Sievers EL.

Nat Biotechnol. 2012 Jul 10;30(7):631-7. doi: 10.1038/nbt.2289.

PMID:
22781692
[PubMed - indexed for MEDLINE]
17.

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK, Frost P.

Curr Opin Pharmacol. 2003 Aug;3(4):386-90. Review.

PMID:
12901947
[PubMed - indexed for MEDLINE]
18.

Site-specific antibody drug conjugates for cancer therapy.

Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR.

MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022. Review.

PMID:
24423619
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
[PubMed - indexed for MEDLINE]
20.

Brentuximab vedotin.

Deng C, Pan B, O'Connor OA.

Clin Cancer Res. 2013 Jan 1;19(1):22-7. doi: 10.1158/1078-0432.CCR-12-0290. Epub 2012 Nov 15. Review.

PMID:
23155186
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk